Acute Otitis Media, Middle Ear Infection Drug Delivery

Background

Acute Otitis Media (AOM) is a prevalent childhood disease, leading to over 20 million physician visits annually in the United States. With a recurrence rate affecting one third of children by age seven, AOM poses a significant healthcare challenge. Up to 80% of children experience pain during an AOM episode, with about 40% suffering severe pain, especially in the first 24-48 hours. Current guidelines recommend analgesics as essential treatment components due to prolonged discomfort in 30% of cases. However, systemic oral antibiotics, the current treatment standard, require 5-10 days of dosing and expose patients to potential side effects, compliance issues, and rising antibiotic resistance. Traditional treatments fail to maintain effective drug concentrations at the infection site and do not address the root cause of infection, which can persist for months, underscoring the need for localized therapeutic options.

Technology Overview

This invention introduces a cutting-edge non-invasive drug delivery system designed to enhance therapeutic agent flux through the tympanic membrane. The system employs FDA-approved poloxamers in a thermosensitive hydrogel composition capable of transitioning from liquid to gel, allowing sustained and high local concentrations post-administration. It utilizes a combination of therapeutic agents and permeation enhancers, such as sodium dodecyl sulfate, limonene, and bupivacaine, within a matrix-forming agent, poloxamer P188, to overcome the tympanic membrane barrier.

The matrix transitions to a hydrogel at slightly below room temperature, leveraging body heat for administration, ensuring precise drug release directly at the site of infection while minimizing systemic exposure and adverse impacts. This formulation promises effective pain relief in AOM due to enhanced analgesic delivery without the drawbacks of current oral therapies.

Applications

• Treatment and prevention of otitis media in children and adults
• Addressing pain associated with AOM through localized analgesic delivery
• Management of bacterial ear infections (e.g., H. influenzae, S. pneumoniae, or M. catarrhalis)
• Broader adaptability for other conditions requiring trans-tympanic drug administration

Advantages

• Non-invasive, direct drug delivery through enhanced tympanic membrane penetration
• Sustained local drug concentration, reducing systemic side effects and resistance
• Improved patient compliance with single-application therapy
• Effective analgesia through targeted and prolonged pain relief
• Potential reduction in disease recurrence and avoidance of surgical interventions, such as tympanostomy tubes

This innovative hydrogel-based system transforms otitis media treatment, offering robust therapeutic benefits, including optimized drug delivery, analgesic efficacy, and minimized resistance, marking a significant advancement over existing systemic treatments. Its ease of use and adaptability make it a promising choice for healthcare providers, enhancing patient outcomes and standard of care in pediatric ear infections.